Clinical treatment failure after 14 days was significantly more frequent in the sulfadoxine/pyrimethamine group ( 38 of 215 , 18 % ) compared with either the sulfadoxine/pyrimethamine plus amodiaquine group ( two of 164 , 1 % ; p < 0.0001 ) or sulfadoxine/pyrimethamine plus artesunate group ( one of 198 , 1 % ; p < 0.0001 ) .
